The board of directors announces the proposal regarding election of new Board member at the Extra General Meeting on November 28, 2022. The company’s major shareholder proposes that Thomas Eldered is elected member of the Board for the time until the next annual general meeting.

Thomas Eldered, born in 1960, is the founder and main owner of Flerie Invest AB, which holds 40.7 percent of the shares and votes in Xintela. Thomas Eldered was also co-founder of Recipharm AB, where he served as CEO from 2008 to 2021. He is currently chairman of the board of Amarna Therapeutics BV, NorthX Biologics AB and Prokarium Ltd, and a member of the Board of Buzzard Pharmaceuticals AB, Chromafora AB, Flerie Invest AB, Kahr Bio Ltd, Nanologica AB, Toleranzia AB and Sixera Pharma AB, among others. Thomas holds a Master of Science in Industrial Engineering and Management from Linköping University.

“Thomas is one of Sweden’s most successful and experienced entrepreneurs, executives and investors in life sciences. It is an affirmation of Xintela’s excellent growth and development that Flerie Invest and Thomas have joined us as we strive to achieve significant milestones ahead. It gives me great pleasure to welcome Thomas to our Board of Directors on behalf of the entire company”, says Xintela’s Chairman of the Board Gregory Batcheller.